A postdoctoral fellow position is currently available in the lab of Dr. Kristen Pauken in the Department of Immunology at UT MD Anderson Cancer Center. Harnessing the immune system using immune checkpoint inhibitors to treat cancer has revolutionized clinical cancer care, demonstrating remarkable efficacy in diverse cancer types. Despite the clinical successes, overall response rates for most cancers remain below 50%, highlighting the need to better understand immunological drivers of response and resistance to improve outcomes. Moreover, a subset of patients develops autoimmune-like immune-related adverse events, which has limited the utility of this approach. The inability to push the reset button on autoreactive immune responses is becoming a rate limiting step in the effective application of immunotherapy for the treatment of cancer and continues to hamper our ability to treat autoimmunity. Many combination therapies designed to improve efficacy also worsen the rate and severity of...